hrcak mascot   Srce   HID

Izvorni znanstveni članak

The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome

Slavko Orešković
Igor But
Maja Banović
Marina Šprem Goldštajn

Puni tekst: engleski, pdf (212 KB) str. 243-248 preuzimanja: 207* citiraj
APA 6th Edition
Orešković, S., But, I., Banović, M. i Šprem Goldštajn, M. (2012). The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome. Collegium antropologicum, 36 (1), 243-248. Preuzeto s https://hrcak.srce.hr/78820
MLA 8th Edition
Orešković, Slavko, et al. "The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome." Collegium antropologicum, vol. 36, br. 1, 2012, str. 243-248. https://hrcak.srce.hr/78820. Citirano 21.11.2019.
Chicago 17th Edition
Orešković, Slavko, Igor But, Maja Banović i Marina Šprem Goldštajn. "The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome." Collegium antropologicum 36, br. 1 (2012): 243-248. https://hrcak.srce.hr/78820
Harvard
Orešković, S., et al. (2012). 'The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome', Collegium antropologicum, 36(1), str. 243-248. Preuzeto s: https://hrcak.srce.hr/78820 (Datum pristupa: 21.11.2019.)
Vancouver
Orešković S, But I, Banović M, Šprem Goldštajn M. The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome. Collegium antropologicum [Internet]. 2012 [pristupljeno 21.11.2019.];36(1):243-248. Dostupno na: https://hrcak.srce.hr/78820
IEEE
S. Orešković, I. But, M. Banović i M. Šprem Goldštajn, "The Efficacy and Safety of Solifenacin in Patients with Overactive Bladder Syndrome", Collegium antropologicum, vol.36, br. 1, str. 243-248, 2012. [Online]. Dostupno na: https://hrcak.srce.hr/78820. [Citirano: 21.11.2019.]

Sažetak
The aim of the randomised, double blind, placebo controlled study was to evaluate the efficacy, tolerability and safety of solifenacin, a once-daily M3 selective receptor antagonist, in patients with overactive bladder syndrome. Following a single blind 2-week placebo run in period, patients who complained from symptoms of OAB for at least 6 months, were randomized to 4 weeks of solifenacin in 5 mg once daily doses or placebo. 171 patients were enrolled in the study and 157 patients completed the study. Patients with solifenacin had significantly improved micturitions per 24 hours after first week of treatment (1.75±0.63 vs. 2.64±0.48, p<0.001), and after four weeks (1.56±0.58 vs. 2.71±0.45, p<0.001)compared to placebo group. The mean number of urgency episodes per 24 hours had significantly decreased in patients with solifenacin compared to placebo after first week (5.75±1.43 vs. 6.65±0.65, p<0.001), and after four weeks of treatment (5.77± 1.33 vs. 6.54±0.50, p<0.001). Solifenacin was also significantly more effective than placebo in reducing the mean number of episodes of severe urgency from baseline to end point (5.83±1.16 vs. 6.48±0.50, p<0.001). Compared with changes obtained with placebo, episodes of urinary frequency were significanlty reduced after first week (0.3 vs. –0.5, p<0.001) and four weeks check up periods in patients treated with solifenacin (0.19 vs. –0.15, p<0.001). Episodes of nocturia was significantly reduced in patients treated with solifenacin after first week (0.3 vs. –0.5, p<0.001), and after four weeks treatment period (0.45 vs. –0.50, p<0.001). The number of incontinence episodes was also significantly decreased in solifenacin group compared to placebo group after first week (1.06±0.57 vs. 2.74±0.47, p<0.001) and four weeks check up (0.96±0.57 vs. 2.75±0.43, p<0.001). The most common adverse effects with solifenacin were dry mouth and constipation. Adverse effects were mild or moderate severity. The discontinuation rate owing to adverse effects was 4.5%–6.7% with solifenacin and 3.8%–6.1% with placebo, respectively. According to subjective estimation, significant improvement was achieved in 71 (92.21%) of patients treated with solifenacin and in 68(85%) patients treated with placebo there was no change in OAB symptoms compared to baseline values. UDI score was significantly improved after solifenacin (22.26± 5.91 vs. 29.61±8.45, p<0.001) compared to placebo. IIQ score was significantly decreased in patients with solifenacin (36.25±10.34 vs. 46.86±6.81, p<0.001) compared to placebo. In conclusion, solifenacin is a safe and effective treatment alternative for patients with overactive bladder symptoms.

Ključne riječi
solifenacin; overactive bladder syndrom

Hrčak ID: 78820

URI
https://hrcak.srce.hr/78820

Posjeta: 430 *